Extracorporeal photopheresis (ECP) is beneficial in patients with T-cell-mediated disorders, including GvHD, but the underlying immunological mechanisms are incompletely understood. Myeloid-derived suppressor cells (MDSCs) are innate immune cells characterized by their capacity to suppress T-cell proliferation. We quantified MDSCs by flow cytometry in peripheral blood from patients after BMT with GvHD before and after ECP treatment, patients after BMT but without GvHD and age-matched healthy controls. MDSC functionality was analyzed using T-cell proliferation, cytokine release and arginase activity. GvHD patients showed increased baseline percentages of neutrophilic MDSCs (PMN-MDSCs) compared with healthy controls and patients after BMT without GvHD. ECP treatment in GvHD patients rapidly increased circulating percentages of PMN-MDSCs. Functionally, PMN-MDSCs efficiently dampened Th1 and Th17 responses and were paralleled by an increase of cellular and extracellular arginase activity. Following ECP longitudinally over 16 weeks, two GvHD responder subgroups were identified, with group one continuously increasing PMN-MDSCs and group two with stable or decreasing PMN-MDSCs over time. This study demonstrates for the first time that ECP increases T-cell-dampening PMN-MDSCs in GvHD patients, a finding that should be confirmed in larger series of GvHD patients.
INTRODUCTION
Extracorporeal photopheresis (ECP) is a leukapheresis-based immunomodulatory approach, 1 combining psoralen and UVA radiation, and has been shown to be efficient in a variety of T-cellmediated diseases, including severe steroid-resistant, acute 2 or chronic GvHD (aGvHD or cGvHD). 3, 4 Despite its clinical effectiveness, the immunomodulatory mechanisms of ECP are not fully understood. 5 Previous studies proposed triggering of lymphocyte, monocyte and natural killer cell apoptosis, 6 the induction of regulatory T cells (Tregs), [7] [8] [9] including enhancement of Treg function, 10 modulation of pro-inflammatory cytokines and/ or induction of tolerogenic dendritic cells [11] [12] [13] [14] as potential modes of ECP action. Immature B-cell subsets and levels of B-cell activating factor have been shown to serve as clinical ECPresponse markers. 15, 16 However, the precise underlying immunological mechanism(s) by which ECP downregulates T-cell responses remain controversially discussed and incompletely defined. 17 Myeloid-derived suppressor cells (MDSCs) represent an innate immune cell population characterized by their capacity to potently suppress T-cell proliferation and T-cell cytokine responses. 18, 19 Although MDSCs have been initially reported to have a role in cancer, an emerging body of evidence suggests that MDSCs are induced in a broad variety of chronic inflammatory disease conditions as an intrinsic anti-inflammatory mechanism induced to dampen excessive T-cell activities. 20 Functionally, MDSCs are comparable to Tregs, but can be characterized and isolated based on surface marker expression profiles. Previous studies in mice showed that MDSCs inhibit GvHD via an arginase-1-dependent mechanism 21 and that ECP attenuates GvHD through bone-marrow-derived effectors, 22 but human studies on the role of MDSCs in GvHD and the potential effects of ECP remained elusive. Here we demonstrate that ECP increases a distinct subpopulation of neutrophilic MDSCs (PMN-MDSCs) in GvHD patients, which control T-cell responses.
MATERIALS AND METHODS

Patients and ECP treatment
Twenty-five patients with GvHD, six patients after BMT but without GvHD and 24 age-matched healthy control subjects were included in the study (for details see Table 1 ), with 11 pediatric (mean age: 7 years) and 14 adult (mean age: 42.5 years) GvHD patients. Diagnoses were hematological disease (AML, ALL, CML, MDS, MPN, aplastic anemia and b-thalassemia major), osteopetrosis or neuroblastoma. All patients had received an allogeneic hematopoietic SCT (HSCT). At the time when ECP was initiated, all patients had aGvHD (n ¼ 18) or cGvHD (n ¼ 7) and were treated with immunosuppressive drugs, including mycophenolate mofetil, steroids, infliximab, tacrolimus and sirolimus. aGvHD and cGvHD were scored according to the NIH Consensus Conference and the Glucksberg criteria 23 as described previously in detail. [24] [25] [26] aGvHD was graded by staging the affected organs, particularly skin, liver and gut (stage 1-4) and subsequently determining an overall grade (grade I-IV). 2 Grading of cGvHD was performed by scoring the organ involvement (score 0-3) and global severity grading (mild, moderate, severe). Mild cGvHD implicating no clinically relevant functional impairment was characterized by involvement of p2 organs (except of the lung) with a maximum score of 1 in all affected organs. Moderate cGvHD (clinically relevant but no major functional impairment) was characterized as involvement of at least one organ with a maximum score of 2 in all affected organs or involvement of p3 organs with a maximum score of 1 or involvement of the lung with a score of 1. Severe cGvHD (major functional impairment with a score of 3 of involved organs or a score of 2-3 of the lung). Bronchiolitis obliterans syndrome was diagnosed according to the NIH definition. 26 CR was defined as complete regression of GvHD manifestations, PR as significant improvement of GvHD manifestations, considering one or more of the following items: involved skin area, volume of diarrhea, bilirubin level, pulmonary function tests (FEV1) and/or histopathology. Complete or PR was defined to occur within 3 months after initiation of ECP for a duration of at least 3 weeks. No remission was defined as an absence of significant clinical changes of GvHD, including only slight or short improvement or worsening of disease. GvHD was treated clinically according to EBMT guidelines with systemic steroids. In case of refractory disease, mycophenolate mofetil, tacrolimus, infliximab, highdose steroids or a combination of these agents were added as second-line treatment together with ECP. ECP was performed as described previously in detail. 2, 27 In brief, the Cellex system (Therakos, USA) was used with a protocol of two treatments per week for the first 4 weeks and two treatments every other week for the following 12 weeks. A blood volume of 750-1500 mL was processed according to the body weight of the patients and white blood cells were separated from RBCs. The leukocytes were pretreated with Methoxsalen and afterwards irradiated with UVA light, before returning them to the patient. The institutional Review Board/Ethical committee of the University of Tü bingen approved these analyses. This study was performed according to the recently revised Helsinki Protocol.
Cell isolation and flow cytometry
PBMCs were prepared from peripheral blood samples by Ficoll density gradient sedimentation (Lymphocyte Separation Medium, Biochrom, Berlin, Germany) and washed twice in RPMI 1640 medium. Trypan blue staining solution at 0.5% differentiated viable and nonviable cells and Figure 1 and Supplementary Figure 1 ). For MDSC isolation, cells were obtained from the PBMC fraction and labeled with anti-CD66b-fluorescein isothiocyanate (FITC) followed by two sequential anti-FITC magnetic bead separation steps (Miltenyi Biotech, Bergisch Gladbach, Germany), according to the manufacturer's protocol. Magnetic cell separation (MACS) had no relevant effect on the phenotype of MDSCs (Supplementary Figure 3) . Purity of CD66b þ cells after separation was 495% as assessed by flow cytometry. For cytospin stainings 5 Â 10 4 cells were centrifuged in a Cytospin 3 centrifuge (Shandon, Thermo Fisher Scientific, Waltham, MA, USA) at 800 rpm for 15 min and stained after MayGrü nwald-Giemsa. Abs against CD3, CD4, CD8, CD14, CD16, CD66b, CD124 (IL-4 Receptor a), CD184/CXCR4 and HLA-DR were purchased from BD Pharmingen. Abs against CD33 were purchased from Miltenyi Biotech. Mouse IgG1-FITC, Mouse IgM-FITC, Mouse IgG1-PE and Mouse IgG1-APC (BD Pharmingen, San Diego, CA, USA) were used as isotype controls. Results were expressed as percent of positive cells and mean fluorescence intensity. Calculations were performed with BD CellQuest analysis software. For Th17 cell staining, 2.5 Â 10 6 PBMCs were stimulated overnight with 10 ng/mL phorbol 12-myristate 13-acetate and 1 mg/mL ionomycin (SigmaAldrich, St Louis, MO, USA) in the presence of GolgiPlug (BD Biosciences, San Jose, CA, USA). After cell surface staining with anti-CD4 (eBioscience, San Diego, CA, USA), cells were fixed and permeabilized (Cytofix/Cytoperm; BD Biosciences) and stained with Alexa Fluor 647-conjugated anti-IL17A (eBioscience). As a control for cellular activation and intracellular staining, CD4
þ T cells were also evaluated for IFN-g production (FITC-conjugated;
PBMCs were stained with CD4-FITC and CD25-PE (BD Biosciences). After cell surface staining cells were fixed and permeabilized (Cytofix/Cytoperm; BD Biosciences) and intracellularly stained with Alexa Fluor 647 anti-human FOXP3 (BioLegend, San Diego, CA, USA). Isotype controls were stained with CD4-FITC and IgG1-Alexea 647 (BioLegend).
T-cell suppression assay
Responder-PBMCs were obtained from healthy volunteers and stained with carboxyfluoresceinsuccinimidyl ester according to the manufacturer's protocol (Invitrogen, Carlsbad, CA, USA). PBMCs were stimulated with 100 U/mL IL-2 (R&D Systems, Minneapolis, MN, USA) and 1 mg/mL OKT3 (Janssen Cilag, Saunderton, UK). In a standardized way, 60 000 PBMCs per well in RPMI1640 (Biochrom) were seeded in a 96-well microtitre plate and 10 000-30 000 MDSC in RPMI1640 or as control isolated conventional non-MDSC neutrophils in RPMI1640 or RPMI1640 only was added. The cell culture was supplemented with 10% heat-inactivated human serum, 2 mM glutamine, 100 IU/mL penicillin and 100 mg/mL streptomycin. After 96 h of incubation in a humidified atmosphere at 37 1C and 5% CO 2 cells were harvested and supernatants were frozen in À 20 1C. Carboxyfluoresceinsuccinimidyl ester (CFSE)-fluorescence intensity was analyzed by flow cytometry to determine polyclonal T-cell proliferation.
Arginase activity
Arginase activity was measured in the PMN-MDSC-containing PBMC fraction and in matched serum samples from GvHD patients directly before and after an ECP procedure using the QuantiChrom Arginase Assay Kit (BioAssay Systems, Hayward, CA, USA). Unit definition: 1 unit of arginase converts 1 mmole of L-arginine to ornithine and urea per minute at pH 9.5 and 37 1C.
Cytokine analysis
Released IFN-gamma, IL-12 and IL-17 proteins were quantified using the Bioplex protein multi-array system (Bioplex Pro human cytokine array, 
Statistical analysis
Statistical analysis was done using GraphPad Prism 5.0 (Graph Pad Software, La Jolla, CA, USA). Differences between the groups were determined by Students' t-test. A P-value of o0.05 was considered to be significant.
RESULTS
ECP rapidly increases neutrophilic MDSCs in GvHD patients
By studying the PBMC fraction from a pediatric GvHD patient before and after a single ECP session, we initially noticed a distinct low-density granulocytic cell population that was substantially increased after ECP treatment. We applied several surface markers and found that this SCC high population was CD33 þ and CD66b þ ( Figure 1a and Supplementary Figure 1) , indicating them to be myeloid neutrophilic cells. Further immunological characterization demonstrated that this myeloid cell population was HLA-DR low , CD124
þ /IL-4Ra þ and CD184 þ /CXCR4 þ . When viewed in combination, these markers were suggestive of a granulocytic/neutrophilic MDSC subtype (PMN-MDSCs). 18, 29 Percentages of monocytic MDSCs in peripheral blood were substantially lower (monocytic MDSCs mean 0.12% before ECP) compared with PMN-MDSCs (mean 6% before ECP) in our patient cohorts and did not change significantly upon ECP treatment (Supplementary Figure 2) . We therefore systematically followed up on the observation that ECP Table 1 . These studies (i) showed that baseline percentages of PMN-MDSCs were already increased in peripheral blood from GvHD patients before ECP treatment compared with age-matched healthy controls or patients after HSCT but without GvHD and (ii) confirmed our initial observation in this larger GvHD patient cohort (n ¼ 25) that ECP treatment rapidly and significantly increased a myeloid cell type resembling PMN-MDSCs in the majority of our GvHD patients studied (Figure 1b) .
Neutrophilic MDSCs functionally suppress T-cell responses
To analyze whether this PMN-MDSC cell type is functional in suppressing T cells, we isolated these cells using MACS technology and assessed their impact on polyclonal T-cell proliferation. PMNMDSCs retained their characteristic surface marker profiles after the MACS isolation procedure (Supplementary Figure 3) . These studies demonstrated that PMN-MDSCs efficiently suppressed both CD4 þ and CD8 þ T-cell proliferation in a dose-dependent manner, whereas autologous conventional control neutrophils had no effect on T-cell proliferation under the same experimental conditions (Figure 2a and Supplementary Figure 4) . Further functional read-out studies provided evidence that ECP-increased PMN-MDSCs differentially dampened Th1 and Th17 cytokine production by T cells, an effect that was more pronounced for IL-17 and IFN-g compared with IL-12 and stronger for PMN-MDSC-T-cell co-culture assays than reflected in longitudinal serum cytokine levels (Figure 2b, Supplementary Figure 5 and Supplementary Figure 6 ). In combination, these analyses showed that the neutrophilic myeloid cell population increased by ECP treatment indeed controls T-cell responses and can therefore be termed as a bona fide MDSC subpopulation according to the current view. 18, 30 Given the induction of functional PMN-MDSCs, we next asked which mechanism is employed by these cells to downregulate T-cell responses. Several factors have been involved into the generation and functionality of MDSCs, particularly arginase, Signal Transducer and Activator of Transcription 3 (STAT3), indoleamine 2,3-dioxygenase (IDO), reactive oxygen species and others. 18, 19 As previous studies found that ECP enhances arginase I mRNA expression and enzyme activity in GvHD patients, 31 we focused on this pathway in our study. Our analyses demonstrated that ECP treatment increased arginase I activity both extracellularly in serum and intracellularly in the PMN-MDSC-containing PBMC fraction in GvHD patients, with PMN-MDSCs showing tendentially higher arginase I activity compared with autologous PBMCs (Figure 2c and Supplementary Figure 7) . Inhibition of arginase activity dampened PMN-MDSC-mediated suppression of CD4 þ , but not CD8 þ T-cell proliferation (Supplementary Figure 8) .
Longitudinal effects of ECP on neutrophilic MDSCs in GvHD patients
After having observed the induction of PMN-MDSCs in the peripheral blood of GvHD patients upon single ECP treatments, we longitudinally followed up this effect using a well-established sequential ECP treatment regimen over 16 weeks. 27 We simultaneously compared the kinetics of PMN-MDSCs, FOXP3-expressing T cells and IL-17-expressing T cells in the treatment course of ECP. These studies demonstrated that percentages of PMN-MDSCs increased with a maximum of 2 weeks after start of the ECP and then decreased slightly until 16 weeks of follow-up (Figure 3a) . Percentages of FOXP3-expressing T cells did not increase substantially in our GvHD patient cohort after ECP treatment. However, because of the lack of a more extensive Treg phenotyping 32, 33 in our protocol, FOXP3-expressing T cells in our study cannot be equated with Tregs. Unexpectedly, percentages of IL-17-expressing T cells initially increased after ECP in GvHD patients, but dropped later to percentages lower than before ECP. These longitudinal studies also revealed two distinct subgroups of GvHD patients: (i) longitudinal 'MDSC responders' (n ¼ 14), who increased their PMN-MDSCs after longitudinal ECP treatment, and longitudinal 'MDSC non-responders' (n ¼ 11), who did not increase their PMN-MDSC percentages after ECP treatment over time (Figure 3b ). When analyzing our whole GvHD patient cohort, neither percentages of PMN-MDSCs, percentages of FOXP3-expressing T cells nor percentages of IL-17-expressing T cells statistically correlated with the clinical response (remission) to ECP. However, within the 'MDSC responder' subgroup (Figures 3b  and c) , we observed that GvHD patients with PR or CR showed an incremental rise of PMN-MDSCs over time, whereas GvHD patients without remission showed a transient, but not persistent, PMN-MDSC increase (Figure 3c ). By subgrouping our mixed GvHD patient cohort into patients with aGvHD versus cGvHD, we observed that the increasing effect of longitudinal ECP treatment on PMN-MDSCs was confined to patients with aGvHD (Supplementary Figure 9) . When analyzing the suppressive potency of isolated PMN-MDSCs on effector T-cell proliferation, we observed that longitudinal ECP treatment also enhanced the cellular capacity of PMN-MDSCs to dampen T-cell proliferation (Supplementary Figure 10) . In combination, these longitudinal studies suggest that ECP treatment modulates myeloid and T-cellular immune responses over time by increasing PMN-MDSCs quantitatively and boostering their suppressive capacity qualitatively. No statistically significant associations were found between PMN-MDSCs and immunosuppressive treatments, such as steroids, in the GvHD patients analyzed in our study.
DISCUSSION
The immunomodulatory mode of action of ECP treatment in GvHD and other T-cell-mediated diseases remains a matter of debate. 5, 6, 14, 17, [34] [35] [36] [37] Our studies demonstrate that ECP treatment rapidly augments PMN-MDSCs, which dampen Th1 and Th17 T-cell responses. Therefore, these studies suggest that, in addition to inducing lymphocyte apoptosis and modulating adaptive immunity, ECP acts on the innate arm of the immune system by rapidly inducing a neutrophilic immunomodulatory MDSC population.
Mechanistically, the effect of ECP on percentages of PMNMDSCs was paralleled by an enhancement of the suppressive function of MDSCs on effector T cells and an increased arginase activity both at cellular and extracellular level, suggesting that (i) ECP has a dual effect on MDSC numbers and function and (ii) ECP-mediated immunomodulation may involve an arginasemediated mechanism, consistent with previous observations. 31 Arginase depletes arginine from the surrounding microenvironment and thereby impairs T-cell functionalities. MDSCs have been described to express and actively utilize arginase I 38, 39 and BM MDSCs were found to inhibit GvHD via an arginase-1-dependent mechanism. 21 When viewed in combination, these lines of evidence, together with our findings, suggest that MDSCderived arginase activity could have a causative role in mediating the immunomodulatory effects of ECP treatment on T-cell homeostasis in GvHD. However, inhibiting arginase activity in our MDSC assays using chemical inhibitors showed only moderate effects that were restricted to CD4 þ T cells and failed to fully abrogate PMN-MDSC functionality in our assays in vitro, an issue that could be due to redundant mechanisms involved in PMN-MDSC-T-cell interactions and/or due to limited potency and selectivity of this inhibitor, necessitating future studies using siRNA knockdown approaches.
Notably, GvHD patients in our study before ECP treatment already showed increased baseline percentages of PMN-MDSCs in the circulation compared with age-matched healthy control subjects as well as compared with patients after HSCT but without GvHD, which may be due to the notion that MDSCs are believed to accumulate generally under chronic inflammatory conditions in order to counterregulate overshooting T-cell responses. 20 We have currently no clear mechanistic explanation for the mechanisms by which ECP increases MDSCs, but speculate, based on the literature on MDSC induction and psoralen/UVA effects, that reactive oxygen species might have a central role in this induction process. Psoralen together with UVA have been used in standard ECP applications for a long time and are known to induce reactive oxygen species, 40 which, in turn, are known inducers of MDSC formation. 30 Together with the inflammatory microenvironment in GvHD, particularly endogenous damage-associated molecular patterns, pro-inflammatory cytokines or chemokines, alarmins and acute phase proteins, such as S100 proteins or serum amyloid A, 41 we speculate that ECP-dependent reactive oxygen species might increase PMN-MDSCs in GvHD patients, hypotheses that should be tested in future studies.
Longitudinally, no significant effects of ECP on FOXP3-expressing T cells were found in our GvHD follow-up cohort. We have currently no clear explanation for this discrepancy between our findings and previous murine and human studies on Tregs and ECP treatment. 17 Given different and improved Treg characterization protocols and quantification strategies and the recently appreciated plasticity of Tregs, 42 including their overlap with Th17 cells, we speculate that our gating strategy, based on FOXP3-expressing Tregs, differs methodologically from previously applied settings. Importantly, FOXP3 protein expression is not specific for Tregs, but can be also found in activated and post-activated T-cell subsets, limiting the conclusions that can be drawn from our T-cell analysis. Alternatively, PMN-MDSCs could interfere with Treg homeostasis in vivo as recently demonstrated in murine cancer studies. 43 Nevertheless, our data indicates that FOXP3-expressing T cells and Th17 cells differ substantially in their longitudinal ECP response characteristics, suggesting that further in-depth T-cell phenotyping is required to fully understand the effects of ECP on T-cell homeostasis. Although percentages of PMN-MDSCs increased significantly upon ECP treatment, absolute numbers increased only tendentially, but not in a statistically significant manner (Supplementary Figure 11) . This result is probably due to the observation that the total PBMC fraction decreased upon single ECP treatments, which affects the calculation of MDSC percentages. As the relationship between MDSCs and T cells is essential for their functional interaction, we speculate that percentages rather than absolute numbers reflect this immune interaction in vivo more precisely. Loss of PBMCs could be due to apoptosis induction by ECP, 6 suggesting that PMN-MDSC might be less susceptible towards ECP-mediated apoptosis, an issue that deserves further investigation. Murine studies provided evidence that bone-marrow-derived MDSCs inhibit GvHD in vivo through an arginase-dependent mechanism. 21 However, the relevance of these findings for human GvHD and the potential effects of ECP in this setting have remained elusive so far. We demonstrate here that PMN-MDSCs are increased at baseline in GvHD patients and are further enhanced in a rapid manner through ECP treatment. However, the rapid effect of ECP treatment on MDSCs was longitudinally only maintained in a subpopulation of GvHD patients. Given the heterogeneity of our GvHD patients, including both pediatric as well as adult patients, statistical analyses failed to identify factors that allow the prediction of which GvHD patients respond over time to ECP treatment with an MDSC increase. Nevertheless, we observed longitudinally that the effects of ECP on both MDSCs and clinical GvHD response parameters were more pronounced in pediatric compared with adult GvHD patients and were largely confined to aGvHD patients (Supplementary Figure 8 and data not shown). Future studies in larger and more homogeneous GvHD patient cohorts are required to compare PMN-MDSCs response characteristics between aGvHD and cGvHD patients and to systematically assess the effect of immunosuppressive treatments on PMN-MDSCs and their influence on the effect of ECP on PMNMDSCs in these patient groups.
In summary, these studies demonstrate for the first time that ECP treatment in GvHD patients increases a distinct subset of innate immune cells, namely neutrophilic MDSCs, which modulate Th1 and Th17 responses. Induction of PMN-MDSCs may represent an underlying mechanism of the immunomodulatory effect of ECP in GvHD and other T-cell-mediated diseases.
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